Mean percent changes from baseline at Week 24 were 0.0% versus 2.5% for total cholesterol, and -1.0% versus 2.9% for LDL cholesterol in the placebo and dapagliflozin 10 mg groups, respectively
The percentage of participants who had weight reduction of 5% or more was 85%, 89%, and 91% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% with placebo
6 Similarly, as GLP-1RAs significantly reduced the risk of MACE, mortality from CV causes, when compared with placebo, ADA has suggested that these medications should be used in patients with underlying cardiovascular disease
Rarer but serious side effects include pancreatitis and risk of thyroid tumors, which a doctor should monitor for during the duration of the drugs use
"As part of an extension trial published a year later, participants regained an average of two-thirds of the weight they shed within 12 months of discontinuing the drug." Within 12 months of discontinuing the drug, participants regained an average of two-thirds of the weight they shed
The impact of hemodialysis on dapagliflozin exposure is not known [see DOSAGE AND ADMINISTRATION , WARNINGS AND PRECAUTIONS , Use In Specific Populations and Clinical Studies ]
